SARS Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Alerts
• Clinical Trials
• Forums

Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50
Conditions:   COVID-19;   SARS-CoV-2 Interventions:   Drug: Ivermectin;   Drug: Placebo Sponsor:   Insud Pharma Terminated (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2023 Category: Research Source Type: clinical trials

Immunogenicity and Safety of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine in Healthy Volunteers
Conditions:   COVID-19;   Vaccines Interventions:   Biological: AdCLD-CoV19-1 OMI;   Biological: Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran) Sponsor:   Cellid Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2023 Category: Research Source Type: clinical trials

Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50
Conditions:   COVID-19;   SARS-CoV-2 Interventions:   Drug: Ivermectin;   Drug: Placebo Sponsor:   Insud Pharma Terminated (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2023 Category: Research Source Type: clinical trials

Immunogenicity and Safety of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine in Healthy Volunteers
Conditions:   COVID-19;   Vaccines Interventions:   Biological: AdCLD-CoV19-1 OMI;   Biological: Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran) Sponsor:   Cellid Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2023 Category: Research Source Type: clinical trials

Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50
Conditions:   COVID-19;   SARS-CoV-2 Interventions:   Drug: Ivermectin;   Drug: Placebo Sponsor:   Insud Pharma Terminated (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2023 Category: Research Source Type: clinical trials

Immunogenicity and Safety of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine in Healthy Volunteers
Conditions:   COVID-19;   Vaccines Interventions:   Biological: AdCLD-CoV19-1 OMI;   Biological: Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran) Sponsor:   Cellid Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2023 Category: Research Source Type: clinical trials